[Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol].
OBJECTIVE
To evaluate the intraocular pressure (IOP) lowering efficacy and safety of Brinzolamide combined with Betaxolol for the Chinese glaucomatous patients.


METHODS
Twenty-six glaucoma patients (44 eyes) diagnosed as primary open angle glaucoma, ocular hypertension and remnant glaucoma (IOP remained high after antiglaucomatous surgeries) were recruited as a research team. After a washing out phase, Brinzolamide 1% combined with Betaxolol 0.25% were administered to them twice daily [(8 +/- 1) o'clock in the morning and (20 +/- 1) o'clock in the evening] respectively. The observing duration was 2 months. The IOP and the side effect before and after the administration of the eyedrops were observed.


RESULTS
The average IOP lowering ranged from 5.03 mm Hg to 6.65 mm Hg (1 mm Hg = 0.133 kPa) (20.55% to 37.30%) after the administration of Brinzolamide 1% combined with Betamolol 0.25% twice a day. The IOP lowering effect was stable and the patients complained little uncomfortable.


CONCLUSIONS
Brinzolamide combined with Betaxolol has significant IOP lowering effect and few side effect for the Chinese people. Brinzolamide can be used as the main medication for the treatment of glaucoma.
Minbin
Yu
Y
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. max-yu@163.net
Fang
Min
M
Ge
Jian
J
Huang
Shengsong
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D015784:Betaxolol / Q000008:administration & dosage*; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D013449:Sulfonamides / Q000008:administration & dosage*; D013843:Thiazines / Q000008:administration & dosage*; D014065:Tonometry, Ocular
D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013843:Thiazines; C111827:brinzolamide; D015784:Betaxolol